Informing the policy process : From efficacy to effectiveness data on pharmacotherapy : The contribution of psychotherapy and pharmacotherapy to National Mental Health Care.
Health care delivery is rapidly changing, but are the right data available to inform the policy process ?
This article illustrates the use of observational data on quality and effectiveness of treatment for anticipating the consequences of alternative forms of health care delivery, with psychotropic medications used as the example.
The data are from the Medical Outcomes Study.
Patients in each specialty sector (general medical provider, psychiatrist, psychologist or master's-level therapist) have unique profiles of use of appropriate psychotropics, and there is less appropriate and less efficient medication management in prepaid than fee-for-service care, especially within psychiatry.
Overall, effective psychotropic medications are underused, reducing the cost-effectiveness of care.
Improving the quality of psychotropic medication management would improve patient functioning outcomes and cost effectiveness of care, but in the absence of compensating strategies, it would also raise treatment costs.
Mots-clés Pascal : Etat dépressif, Chimiothérapie, Psychotrope, Antidépresseur, Soin santé primaire, Politique sanitaire, Analyse coût, Etats Unis, Amérique du Nord, Amérique, Homme, Trouble humeur, Traitement, Soin intégré
Mots-clés Pascal anglais : Depression, Chemotherapy, Psychotropic, Antidepressant agent, Primary health care, Health policy, Cost analysis, United States, North America, America, Human, Mood disorder, Treatment, Managed care
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0409693
Code Inist : 002B02B02. Création : 10/04/1997.